SRC and cancer: Astoundingly, the high-ELF4 cell lines were only significantly more sensitive than the low-ELF4 cell lines to three anti-cancer drugs: dasatinib (p = 1.16 x 10−06), WH-4-023 (p = 0.0027) and Ponatinib (p = 0.034), all of which target the proto-oncogene tyrosine-protein kinase SRC and tyrosine-protein kinase ABL1 (Fig 3B; S2 File).